{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:36:42Z","timestamp":1794245802299,"version":"4.9.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Opioid anesthesia can modulate the impaired immune response and opioid-sparing anesthesia may preserve immune functions. This study was performed to assess the effects of opioid-free anesthesia (OFA) and opioid-based anesthesia (OA) on perioperative macrophages differentiation, cytokine changes, and perioperative complications in locally advanced GC (LAGC) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used quality of recovery-15 (QoR-15) questionnaire scores and visual analog scale (VAS) scores to compare postoperative quality of recovery and pain level. In addition, the adverse reactions of patients in the two groups were compared. The perioperative serum level of inflammatory cytokines and the ratio of macrophage subtypes were detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The OFA group had significantly longer extubation time and PACU stay, whereas the OA group had significantly higher rate of hypotension, higher doses of norepinephrine, higher PONV and dizziness rate, and delayed flatus passage time. The QoR-15 score on postoperative 24 h was significantly higher in OFA group than in OA group. At the end of or after the surgery, the OFA group had higher levels of interleukin (IL)-12, IL-1\u03b2, tumor necrosis factor (TNF)-\u03b1, CD68+CD163\u2212 macrophage rate, but lower levels of IL-10, transforming growth factor (TGF)-\u03b2, and CD68+CD163+ macrophage rate, indicating OFA attenuated perioperative immunosuppression by diminishing M2 and promoting M1 macrophage polarization. And the reversal tendency is more obvious in LAGC patients with neoadjuvant PD-1 inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The OFA may attenuate perioperative immunosuppression by diminishing M2 and promoting M1 macrophage polarization in LAGC patients with neoadjuvant PD-1 inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>http:\/\/gcpgl.sysucc.org.cn<\/jats:uri>\n                      , identifier 2022-FXY-001.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1438859","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T13:38:37Z","timestamp":1729258717000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Opioid\u2212free anesthesia attenuates perioperative immunosuppression by regulating macrophages polarization in gastric cancer patients treated with neoadjuvant PD-1 inhibitor"],"prefix":"10.3389","volume":"15","author":[{"given":"Wenjian","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaopeng","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifeng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.0182","article-title":"Surgical management of gastric cancer: A review","volume":"157","author":"Li","year":"2022","journal-title":"JAMA Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-019-01896-5","article-title":"Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives","volume":"50","author":"Tokunaga","year":"2020","journal-title":"Surg Today"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s13304-018-0539-z","article-title":"Multimodal treatment in locally advanced gastric cancer","volume":"70","author":"Goetze","year":"2018","journal-title":"Updates Surg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"101657","DOI":"10.1016\/j.tranon.2023.101657","article-title":"Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study","volume":"31","author":"Zhang","year":"2023","journal-title":"Transl Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.927781","article-title":"Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02721-w","article-title":"Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial","volume":"30","author":"Yuan","year":"2024","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34296","article-title":"First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis","volume":"152","author":"Liu","year":"2023","journal-title":"Int J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004037","article-title":"Poor clinical outcomes and immunoevasive contexture in intratumoral IL-10-producing macrophages enriched gastric cancer patients","volume":"275","author":"Zhang","year":"2022","journal-title":"Ann Surg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12935-022-02717-5","article-title":"Crosstalk between tumor-associated macrophages and tumor cells promotes chemoresistance via CXCL5\/PI3K\/AKT\/mTOR pathway in gastric cancer","volume":"22","author":"Su","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"108838","DOI":"10.1016\/j.abb.2021.108838","article-title":"Yes associated protein 1 promotes resistance to 5-fluorouracil in gastric cancer by regulating GLUT3-dependent glycometabolism reprogramming of tumor-associated macrophages","volume":"702","author":"He","year":"2021","journal-title":"Arch Biochem Biophys"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0218","article-title":"DKK1 promotes tumor immune evasion and impedes anti-PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer","volume":"10","author":"Shi","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1862520","DOI":"10.1080\/2162402X.2020.1862520","article-title":"M1-like TAMs are required for the efficacy of PD-L1\/PD-1 blockades in gastric cancer","volume":"10","author":"Zhao","year":"2020","journal-title":"Oncoimmunology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s44254-023-00043-1","article-title":"Perioperative multimodal analgesia: a review of efficacy and safety of the treatment options","volume":"2","author":"Kianian","year":"2024","journal-title":"Anesthesiology Perioperative Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aew050","article-title":"How can we prevent opioid induced hyperalgesia in surgical patients","volume":"116","author":"Fletcher","year":"2016","journal-title":"Br J Anaesth"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000000975","article-title":"Practice guidelines for the prevention, detection, and management of respiratory depression associated with neuraxial opioid administration: an updated report by the american society of anesthesiologists task force on neuraxial opioids and the American society of regional anesthesia and pain medicine","volume":"124","author":"Rathmell","year":"2016","journal-title":"Anesthesiology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejphar.2013.09.074","article-title":"Opioid induced nausea and vomiting","volume":"722","author":"Smith","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2014.20.9.948","article-title":"Development and validation of a risk score to identify patients at high risk for opioid-related adverse drug events","volume":"20","author":"Minkowitz","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2007.01.001","article-title":"Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity and metastatic colonization in rats in comparison with morphine or fentanyl treatment","volume":"21","author":"Franchi","year":"2007","journal-title":"Brain Behav Immun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s44254-023-00049-9","article-title":"Expression heterogeneity, tumor immune characteristics and the prognosis effects of OPRL1 in patients with tumors: a pan-cancer study combined with bioinformation analyses and in vitro validation","volume":"2","author":"Wang","year":"2024","journal-title":"Anesthesiology Perioperative Sci"},{"key":"B24","article-title":"Effect of different anaesthesia methods on perioperative cellular immune function and long-term outcome in patients undergoing radical resection of esophageal cancer: a prospective cohort study","volume":"13","author":"Cong","year":"2021","journal-title":"Am J Transl Res"},{"key":"B25","article-title":"Effect of anaesthetic technique on immune cell infiltration in breast cancer: a follow-up pilot analysis of a prospective, randomised, investigator-masked study","volume":"35","author":"Desmond","year":"2015","journal-title":"Anticancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nri3712","article-title":"Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"104723","DOI":"10.1016\/j.oraloncology.2020.104723","article-title":"Targeting tumor-associated macrophages in head and neck squamous cell carcinoma","volume":"106","author":"Li","year":"2020","journal-title":"Oral Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nri2448","article-title":"Exploring the full spectrum of macrophage activation","volume":"8","author":"Mosser","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nri3088","article-title":"Transcriptional regulation of macrophage polarization: enabling diversity with identity","volume":"11","author":"Lawrence","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nat Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0152","article-title":"Tumor-associated monocytes\/macrophages impair NK-cell function via TGFbeta1 in human gastric cancer","volume":"5","author":"Peng","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e318289b84b","article-title":"Development and psychometric evaluation of a postoperative quality of recovery score: the QoR-15","volume":"118","author":"Stark","year":"2013","journal-title":"Anesthesiology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S392784","article-title":"Effects of the different doses of esketamine on postoperative quality of recovery in patients undergoing modified radical mastectomy: A randomized, double-blind, controlled trial","volume":"16","author":"Zhu","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-022-00442-5","article-title":"Effects of systemic lidocaine versus dexmedetomidine on the recovery quality and analgesia after thyroid cancer surgery: A randomized controlled trial","volume":"11","author":"Shu","year":"2022","journal-title":"Pain Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjane.2021.10.005","article-title":"Evaluation of lignocaine, dexmedetomidine, lignocaine-dexmedetomidine infusion on pain and quality of recovery for robotic abdominal hysterectomy: a prospective randomized controlled trial","volume":"72","author":"Sivaji","year":"2022","journal-title":"Braz J Anesthesiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1101449","article-title":"Perioperative lidocaine and dexmedetomidine intravenous infusion reduce the serum levels of NETs and biomarkers of tumor metastasis in lung cancer patients: A prospective, single-center, double-blinded, randomized clinical trial","volume":"13","author":"Ren","year":"2023","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-022-01487-4","article-title":"Clinical effects of remimazolam alone or in combination with dexmedetomidine in patients receiving bronchoscopy and influences on postoperative cognitive function: a randomized-controlled trial","volume":"45","author":"Gao","year":"2023","journal-title":"Int J Clin Pharm"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000003725","article-title":"Balanced opioid-free anesthesia with dexmedetomidine versus balanced anesthesia with remifentanil for major or intermediate noncardiac surgery","volume":"134","author":"Beloeil","year":"2021","journal-title":"Anesthesiology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12871-022-01662-0","article-title":"Subanaesthetic dose of esketamine during induction delays anaesthesia recovery a randomized, double-blind clinical trial","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Anesthesiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.874589","article-title":"Tumor-associated macrophages regulate PD-1\/PD-L1 immunosuppression","volume":"13","author":"Pu","year":"2022","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","article-title":"Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol Cancer"},{"key":"B43","first-page":"51","article-title":"Opioid peptides in immune cells","volume":"521","author":"Smith","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00535-013-0753-x","article-title":"Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives","volume":"49","author":"Sobczak","year":"2014","journal-title":"J Gastroenterol"},{"key":"B45","article-title":"Effects of fentanyl anesthesia and sufentanil anesthesia on regulatory T cells frequencies","volume":"7","author":"Gong","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"11389","DOI":"10.1038\/srep11389","article-title":"Morphine modulates interleukin-4- or breast cancer cell-induced pro-metastatic activation of macrophages","volume":"5","author":"Khabbazi","year":"2015","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1852","article-title":"Identifying clear cell renal cell carcinoma coexpression networks associated with opioid signaling and survival","volume":"81","author":"Scarpa","year":"2021","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"106388","DOI":"10.1016\/j.intimp.2020.106388","article-title":"Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax\/Bcl-2\/caspase-3\/PARP pathway","volume":"83","author":"Ma","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12967-021-02784-8","article-title":"The role of opioids in cancer response to immunotherapy","volume":"19","author":"Botticelli","year":"2021","journal-title":"J Transl Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1438859\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T13:38:40Z","timestamp":1729258720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1438859\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2024.1438859"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1438859","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2024.1438859.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2024.1438859.s002","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"article-number":"1438859"}}